However, there is little evidence concerning the prevalence of anti-DI antibodies early in the disease course of patients with SLE and whether presence of these antibodies with or without aCL and anti-β2GPI positivity delineates patient groups with higher risk of mortality or vascular events (VE) over many years of follow-up. Here, ACLY is linked to systemic lupus erythematosus.